MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag203

Медицинская библиотека · The oncologist · 2026

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.

Rebuzzi Sara Elena, Ghose Aruni, Rudman Sarah, Venugopal Balaji, Young Kate, Frazer Ricky Dylan, Ayodele Olubukola, Stares Mark, O'Carrigan Brent, Ali Waqas, McGrane John, Jain Ankit, Fiala Ondrej, Chauhan Vishwani, Michael Agnieszka, Zarkar Anjali, Kapur Gaurav, Charnley Natalie, Afshar Mehran, Vengalil Salil, Forde Caroline, Brown Janet, Ürün Yüksel, Bianchini Diletta, Bahl Amit, Srihari Narayanan, Di Costanzo Fabrizio, Smalley Benjamin, Parkes Joanne, Crabb Simon, Vasudev Naveen, Poprach Alexandr, Brown Nicholas, James Lijo, Haywood Sophia, Tapia Jose, Vijay Anupama, Parry Jane, Cheung Michael, Mahajan Ishika, Moon Niall O, Abrol Ritika, Tkadlecová Michaela, Soe Yamin Shwe Yee, Zargham Anum, Smith Michelle, Ashley Sophie, Hardy Orla, Patel Grisma, Tun Kyaw Kyaw, Johnston Emma, Sarwer Abdullah, Bölek Hatice, Shrestha Roshani, Challapalli Amarnath, Meegan James, Anpalakhan Shobana, Buono Francesco, Kolarikova Eva, Leung David Ka-Wai, Murianni Veronica, Catalano Fabio, Bimbatti Davide, Buti Sebastiano, Signori Alessio, Fornarini Giuseppe, Rescigno Pasquale, Teoh Jeremy Yuen Chun, Banna Giuseppe Luigi

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Effective risk stratification is essential for guiding treatment decisions in patients with metastatic renal cell carcinoma (mRCC). The Meet-URO score is a novel prognostic model that integrates the International Metastatic RCC Database Consortium (IMDC) criteria with neutrophil-to-lymphocyte ratio (NLR) and the presence of bone metastases. Developed in the immunotherapy era, it has demonstrated superior prognostic accuracy compared to the IMDC score across various clinical settings and treatment strategies. Its validation in the context of first-line immune-based combinations has been awaited.

METHODS

External validation of Meet-URO was performed using a large retrospective real-world cohort of mRCC patients treated with first-line immune-based combinations. Secondary analyses included a comparison with the IMDC score for predicting overall survival (OS) and progression-free survival (PFS). Additionally, restricted mean survival time (RMST) was assessed.

RESULTS

A total of 1,418 patients were included in the analysis: 54% received ICI-ICI regimen (nivolumab plus ipilimumab), while 46% received the ICI-TKI combination. At baseline, 52.5% of patients had an NLR ≥ 3.2, and 32% had bone metastases. After a median follow-up of 26.8 months, the median OS and median PFS were 34.7 and 11.3 months, respectively. Meet-URO demonstrated effective prognostic stratification, identifying patient groups with markedly different outcomes (median OS 11.5-51.4 months; 3-year OS 26-66%; RMST 20.0-42.8 months). Compared to IMDC, Meet-URO showed a significantly better OS (c-index 0.675 vs 0.643; Δc = 0.032, P < .001) and PFS (c-index 0.60 vs 0.58; P < .001) prediction performance.

CONCLUSIONS

Meet-URO demonstrated robust prognostic accuracy. Its integration into routine clinical practice and use as a stratification factor in clinical trials may support more personalized treatment strategies and enhance clinical trial design.

Для цитирования: Rebuzzi Sara Elena, Ghose Aruni, Rudman Sarah, Venugopal Balaji, Young Kate, Frazer Ricky Dylan, Ayodele Olubukola, Stares Mark, O'Carrigan Brent, Ali Waqas, McGrane John, Jain Ankit, Fiala Ondrej, Chauhan Vishwani, Michael Agnieszka, Zarkar Anjali, Kapur Gaurav, Charnley Natalie, Afshar Mehran, Vengalil Salil, Forde Caroline, Brown Janet, Ürün Yüksel, Bianchini Diletta, Bahl Amit, Srihari Narayanan, Di Costanzo Fabrizio, Smalley Benjamin, Parkes Joanne, Crabb Simon, Vasudev Naveen, Poprach Alexandr, Brown Nicholas, James Lijo, Haywood Sophia, Tapia Jose, Vijay Anupama, Parry Jane, Cheung Michael, Mahajan Ishika, Moon Niall O, Abrol Ritika, Tkadlecová Michaela, Soe Yamin Shwe Yee, Zargham Anum, Smith Michelle, Ashley Sophie, Hardy Orla, Patel Grisma, Tun Kyaw Kyaw, Johnston Emma, Sarwer Abdullah, Bölek Hatice, Shrestha Roshani, Challapalli Amarnath, Meegan James, Anpalakhan Shobana, Buono Francesco, Kolarikova Eva, Leung David Ka-Wai, Murianni Veronica, Catalano Fabio, Bimbatti Davide, Buti Sebastiano, Signori Alessio, Fornarini Giuseppe, Rescigno Pasquale, Teoh Jeremy Yuen Chun, Banna Giuseppe Luigi. Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag203.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.